{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:22:45Z","timestamp":1760296965637},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1038\/sj.bmt.1703925","type":"journal-article","created":{"date-parts":[[2003,5,6]],"date-time":"2003-05-06T11:30:21Z","timestamp":1052220621000},"page":"775-782","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and feasibility of CHOP\/rituximab induction treatment followed by high-dose chemo\/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma"],"prefix":"10.1038","volume":"31","author":[{"given":"G","family":"He\u00df","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Flohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kolbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-G","family":"Derigs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,5,6]]},"reference":[{"key":"BF1703925_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJM198706113162402","volume":"316","author":"T Takvorian","year":"1987","unstructured":"Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987; 316: 1499\u20131505.","journal-title":"N Engl J Med"},{"key":"BF1703925_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540\u20131545.","journal-title":"N Engl J Med"},{"key":"BF1703925_CR3","first-page":"11","volume":"20","author":"C Linassier","year":"1996","unstructured":"Linassier C, Fouillared L, Milpied N et al. Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional therapy: a \u2018France Autogreffe\u2019 study. Cancer Detect Prov 1996; 20: 11\u201319.","journal-title":"Cancer Detect Prov"},{"key":"BF1703925_CR4","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","volume":"88","author":"AS Freedmann","year":"1996","unstructured":"Freedmann AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780\u20132786.","journal-title":"Blood"},{"key":"BF1703925_CR5","first-page":"2715","volume":"94","author":"W Hiddemann","year":"1999","unstructured":"Hiddemann W, Unterhalt IM, Wandt H et al. Myeloablative radiochemotherapy followed by blood-stem cell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: results of a prospective randomized comparison by the German Low-grade Lymphoma Study Group (GLSG). Blood 1999; 94: 2715 (Abstr.).","journal-title":"Blood"},{"key":"BF1703925_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.V97.2.404","volume":"97","author":"S Horning","year":"2001","unstructured":"Horning S, Negrin R, Hoppe R et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission. Results of a phase II clinical trial. Blood 2001; 97: 404\u2013409.","journal-title":"Blood"},{"key":"BF1703925_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJM199111283252201","volume":"325","author":"J Gribben","year":"1991","unstructured":"Gribben J, Freedman A, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525\u20131533.","journal-title":"N Engl J Med"},{"key":"BF1703925_CR8","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","volume":"88","author":"AS Freedman","year":"1996","unstructured":"Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780\u20132786.","journal-title":"Blood"},{"key":"BF1703925_CR9","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","volume":"94","author":"AS Freedman","year":"1999","unstructured":"Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325\u20133333.","journal-title":"Blood"},{"key":"BF1703925_CR10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188\u20132195.","journal-title":"Blood"},{"key":"BF1703925_CR11","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimaeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"BF1703925_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","volume":"109","author":"JM Foran","year":"2000","unstructured":"Foran JM, Gupta RK, Cunningham D et al. A UK multicenter phase II study of Rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81\u201388.","journal-title":"Br J Haematol"},{"key":"BF1703925_CR13","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","volume":"95","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD, Burries HA, Morrissea LH et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low grade non-Hodgkin lymphoma. Blood 2000; 95: 3052\u20133056.","journal-title":"Blood"},{"key":"BF1703925_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101\u2013106.","journal-title":"Blood"},{"key":"BF1703925_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of Rituximab (chimaeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317\u2013324.","journal-title":"J Clin Oncol"},{"key":"BF1703925_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Link BK, Grossbard ML et al. Phase II Study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389\u2013397.","journal-title":"J Clin Oncol"},{"key":"BF1703925_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimaeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268\u2013276.","journal-title":"J Clin Oncol"},{"key":"BF1703925_CR18","first-page":"3507","volume":"98","author":"W Hiddemann","year":"2001","unstructured":"Hiddemann W, Forstpointner R, Fiedler F et al. The addition of Rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantle cell lymphomas (MCL) \u2013 results of a prospective randomized comparison of the German Low Grade Lymphoma Study Group GLSG). Blood 2001; 98: 3507 (Abstract).","journal-title":"Blood"},{"key":"BF1703925_CR19","first-page":"2519","volume":"98","author":"MS Czuczman","year":"2001","unstructured":"Czuczman MS, Grillo-L\u00f3pez AJ, White CA et al. Progression-free survival (PFS) after six years (median) follow up of the first clinical trial of Rituximab\/CHOP chemoimmunotherapy. Blood 2001; 98: 2519 (Abstr.).","journal-title":"Blood"},{"key":"BF1703925_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235\u2013242.","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"BF1703925_CR21","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1093\/annonc\/5.suppl_2.S143","volume":"5","author":"AZS Rohatiner","year":"1994","unstructured":"Rohatiner AZS, Freedman A, Nadler L et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol 1994; 5 (Suppl. 2): S143\u2013S146.","journal-title":"Ann Oncol"},{"key":"BF1703925_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2141.2002.03256.x","volume":"116","author":"M Lazzarino","year":"2002","unstructured":"Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with rituximab mobilization of in vivo purged stem cell, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229\u2013235.","journal-title":"Br J Haematol"},{"key":"BF1703925_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.bmt.1703515","volume":"29","author":"T Flohr","year":"2002","unstructured":"Flohr T, Hess G, Kolbe K et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769\u2013775.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703925_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1046\/j.1365-2141.2000.02084.x","volume":"109","author":"MT Voso","year":"2000","unstructured":"Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside\/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729\u2013735.","journal-title":"Br J Haematol"},{"key":"BF1703925_CR25","first-page":"2832","volume":"98","author":"IW Flinn","year":"2001","unstructured":"Flinn IW, Jones RJ, Goodrich A et al. Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assay. Blood 2001; 98: 2832 (Abstr.).","journal-title":"Blood"},{"key":"BF1703925_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","volume":"6","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, O'Donnell PV, Goodrich A et al. Peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628\u2013632.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1703925_CR27","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","volume":"96","author":"M Magni","year":"2000","unstructured":"Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864\u2013869.","journal-title":"Blood"},{"key":"BF1703925_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.1997.15.2.509","volume":"15","author":"I Majolino","year":"1997","unstructured":"Majolino I, Pearce R, Taghipour G, Goldstone AH . Peripheral blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509\u2013517.","journal-title":"J Clin Oncol"},{"key":"BF1703925_CR29","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244\u20131253.","journal-title":"J Clin Oncol"},{"key":"BF1703925_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","volume":"5","author":"DR Sutherland","year":"1996","unstructured":"Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213\u2013226.","journal-title":"J Hematother"},{"key":"BF1703925_CR31","first-page":"1","volume":"46","author":"J Nicholson","year":"1997","unstructured":"Nicholson J, Hearn T, Cross G et al. revised guidelines for performing CD4+ T-cell determination in persons infected with human immunodeficiency virus. MMWR 1997; 46: 1\u201327.","journal-title":"MMWR"},{"key":"BF1703925_CR32","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/sj.leu.2401172","volume":"12","author":"C Pott","year":"1998","unstructured":"Pott C, Tiemann M, Linke B et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998; 12: 1630\u20131637.","journal-title":"Leukemia"},{"key":"BF1703925_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"52","author":"F Kaplan","year":"1958","unstructured":"Kaplan F, Meier P . Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 52: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BF1703925_CR34","first-page":"115","volume":"26","author":"R Buckstein","year":"1999","unstructured":"Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by \u2018in vivo purging\u2019 with Rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 115\u2013122.","journal-title":"Semin Oncol"},{"issue":"Suppl. 1","key":"BF1703925_CR35","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.bmt.1703296","volume":"29","author":"AM Gianni","year":"2002","unstructured":"Gianni AM, Cortelazzo S, Magni M, Martelli M . Riuximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29 (Suppl. 1): S10\u2013S13.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703925_CR36","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood.V94.12.4029","volume":"94","author":"LA Holmberg","year":"1999","unstructured":"Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 1999; 94: 4029\u20134035.","journal-title":"Blood"},{"key":"BF1703925_CR37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/infdis\/174.5.907","volume":"174","author":"M Boeckh","year":"1996","unstructured":"Boeckh M, Stevens-Ayers T, Bowden RA . Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996; 174: 907\u2013912.","journal-title":"J Infect Dis"},{"key":"BF1703925_CR38","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/blood.V99.4.1486","volume":"99","author":"SL Goldberg","year":"2002","unstructured":"Goldberg SL, Pecora AL, Alter RS et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 1486\u20131888.","journal-title":"Blood"},{"key":"BF1703925_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.bmt.1701069","volume":"21","author":"K Nagafuji","year":"1998","unstructured":"Nagafuji K, Eto T, Hayashi S et al. Fatal cytomegalovirus interstitial pneumonia following autologous peripheral blood stem cell transplantation. Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1998; 21: 301\u2013303.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703925_CR40","doi-asserted-by":"crossref","first-page":"384a","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"S Horwitz","year":"2000","unstructured":"Horwitz S, Breslin S, Negrin R et al. Adjuvant rituximab after autologous peripheral blood stem cell transplantation results in delayed immune reconstitution without increase in infectious complications. Blood 2000; 96: 384a.","journal-title":"Blood"},{"key":"BF1703925_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.bmt.1700621","volume":"19","author":"K Kolbe","year":"1997","unstructured":"Kolbe K, Domkin D, Derigs HG et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143\u2013147.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703925_CR42","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288\u20131294.","journal-title":"J Clin Oncol"},{"key":"BF1703925_CR43","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.V99.3.856","volume":"99","author":"A Rambaldi","year":"2002","unstructured":"Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856\u2013862.","journal-title":"Blood"},{"key":"BF1703925_CR44","first-page":"3502","volume":"98","author":"DG Maloney","year":"2001","unstructured":"Maloney DG, Press OW, Braziel RM et al. A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. Blood 2001; 98: 3502 (Abstr.).","journal-title":"Blood"},{"key":"BF1703925_CR45","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LK Piro","year":"1999","unstructured":"Piro LK, White AJ, Grillo-Lopez et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655\u2013661.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"BF1703925_CR46","first-page":"112","volume":"13","author":"M Ghielmini","year":"2002","unstructured":"Ghielmini M, Schmitt SF, Cogliatti AB et al. Maintenance treatment with 2-monthly rituximab after standard weekly \u00d7 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Ann Oncol 2002; 13 (Suppl 2): 112 (Abstr.).","journal-title":"Ann Oncol"},{"key":"BF1703925_CR47","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1182\/blood.V98.8.2518","volume":"98","author":"MS Czuczman","year":"2001","unstructured":"Czuczman MS, Fallon A, Mohr A et al. Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report. Blood 2001; 98: 2518 (Abstr.).","journal-title":"Blood"},{"key":"BF1703925_CR48","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","volume":"99","author":"JM Timmerman","year":"2002","unstructured":"Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517\u20131526.","journal-title":"Blood"},{"key":"BF1703925_CR49","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/13928","volume":"5","author":"M Bendandi","year":"1999","unstructured":"Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte\u2013monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171\u20131178.","journal-title":"Nat Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703925.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703925","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703925.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:35:59Z","timestamp":1648078559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["BF1703925"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703925","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]},"assertion":[{"value":"14 June 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}